Predicting colorectal cancer recurrence using portal vein blood analysis
A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood: a Multi-center Study
This study is testing if analyzing blood from the portal vein can help predict if colorectal cancer will come back in patients after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Shougang Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06524245 on ClinicalTrials.gov |
What this trial studies
This multi-center study aims to develop a predictive model for colorectal cancer (CRC) recurrence and metastasis through multi-omics analysis of portal vein blood. It will include stage I-IV CRC patients and utilize a nested case-control study and a bidirectional cohort study design. Comprehensive sequencing will be performed on samples from primary tumors, adjacent tissues, normal intestinal tissues, portal vein blood, and peripheral blood to identify biomarkers associated with CRC recurrence. The ultimate goal is to enhance early prediction and intervention strategies for CRC patients post-surgery.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 years or older with histologically confirmed stage I-IV colorectal cancer who can provide necessary blood and tissue samples.
Not a fit: Patients with a prior history of other malignancies or those who have received neoadjuvant therapy before surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accurate method for predicting colorectal cancer recurrence, leading to timely interventions.
How similar studies have performed: Other studies utilizing multi-omics approaches for cancer prediction have shown promise, suggesting potential success for this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Histologically confirmed stage I-IV colorectal cancer (CRC) * Availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood) and primary tumor tissue samples * No neoadjuvant therapy before surgery Exclusion Criteria: * Prior history of other malignancies * Incomplete clinical information or pathology reports * Incomplete follow-up records
Where this trial is running
Beijing, Beijing Municipality
- Peking University Shougang Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Jin Gu, Prof. — Peking University Shougang Hospital
- Study coordinator: Dandan Huang, M.D
- Email: hdn1208@163.com
- Phone: 800-555-5555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.